Arpida’s iclaprim MAA accepted for review by European Medicines Agency
Arpida is seeking approval of intravenous iclaprim in the EU for the treatment of complicated skin and soft tissue infections (cSSTI). Iclaprim is a hospital antibiotic drug candidate
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.